These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24970695)

  • 1. Angiographic evaluation of hepatic arterial injury after cisplatin and Gelfoam-based transcatheter arterial chemoembolization for hepatocellular carcinoma in a 205 patient cohort during a 6-year follow-up.
    Suh CH; Shin JH; Yoon HM; Yoon HK; Ko GY; Gwon DI; Kim JH; Sung KB
    Br J Radiol; 2014 Sep; 87(1041):20140054. PubMed ID: 24970695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiographic evaluation of hepatic arterial damage after transarterial chemoembolization for hepatocellular carcinoma.
    Maeda N; Osuga K; Mikami K; Higashihara H; Onishi H; Nakaya Y; Tatsumi M; Hori M; Kim T; Tomoda K; Nakamura H
    Radiat Med; 2008 May; 26(4):206-12. PubMed ID: 18509720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.
    Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY
    Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of transcatheter arterial chemoembolization with embospheres in treatment of hepatocellular carcinoma.
    Hao MZ; Lin HL; Chen QZ; Hu YB; Chen JB; Zheng JX; Zhou D; Zhang H
    J Dig Dis; 2017 Jan; 18(1):31-39. PubMed ID: 27987344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular complications of hepatic artery after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Sueyoshi E; Hayashida T; Sakamoto I; Uetani M
    AJR Am J Roentgenol; 2010 Jul; 195(1):245-51. PubMed ID: 20566824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of transcatheter arterial chemoembolization with 2-day-soluble gelatin sponge particles for hepatocellular carcinoma-comparison with insoluble gelatin sponge particles.
    Kawai N; Sato M; Minamiguchi H; Ikoma A; Sanda H; Nakata K; Sato H; Sakaguchi H; Nakai M; Sonomura T
    J Vasc Interv Radiol; 2013 Sep; 24(9):1383-90. PubMed ID: 23727419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Incidence and risk factors of acute hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma].
    Jeon SH; Park KS; Kim YH; Shin YS; Kang MK; Jang BK; Chung WJ; Cho KB; Hwang JS
    Korean J Gastroenterol; 2007 Sep; 50(3):176-82. PubMed ID: 17885283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization.
    Kim JH; Yoon HK; Ko GY; Gwon DI; Jang CS; Song HY; Shin JH; Sung KB
    Radiology; 2010 Apr; 255(1):270-7. PubMed ID: 20308463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents.
    Brown DB; Pilgram TK; Darcy MD; Fundakowski CE; Lisker-Melman M; Chapman WC; Crippin JS
    J Vasc Interv Radiol; 2005 Dec; 16(12):1661-6. PubMed ID: 16371533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fever after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis.
    Li CP; Chao Y; Chen LT; Lee RC; Lee WP; Yuan JN; Yen SH; Lee SD
    Scand J Gastroenterol; 2008 Aug; 43(8):992-9. PubMed ID: 19086281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and efficacy of balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization.
    Kim PH; Gwon DI; Kim JW; Chu HH; Kim JH
    Eur Radiol; 2020 Oct; 30(10):5650-5662. PubMed ID: 32409860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcatheter arterial chemoembolization for infiltrative hepatocellular carcinoma: clinical safety and efficacy and factors influencing patient survival.
    Han K; Kim JH; Yoon HM; Kim EJ; Gwon DI; Ko GY; Yoon HK; Ko HK
    Korean J Radiol; 2014; 15(4):464-71. PubMed ID: 25053906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of inoperable hepatocellular carcinoma by transcatheter arterial chemoembolization using an emulsion of cisplatin in iodized oil and gelfoam.
    Ngan H; Lai CL; Fan ST; Lai EC; Yuen WK; Tso WK
    Clin Radiol; 1993 May; 47(5):315-20. PubMed ID: 8389682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arterial dissections during transcatheter arterial chemoembolization for hepatocellular carcinoma: a 19-year clinical experience at a single medical institution.
    Jung E; Shin JH; Kim JH; Yoon HK; Ko GY; Sung KB
    Acta Radiol; 2017 Jul; 58(7):842-848. PubMed ID: 28273730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma.
    Sahara S; Kawai N; Sato M; Tanaka T; Ikoma A; Nakata K; Sanda H; Minamiguchi H; Nakai M; Shirai S; Sonomura T
    Cardiovasc Intervent Radiol; 2012 Dec; 35(6):1363-71. PubMed ID: 22358993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma.
    Habbel VSA; Zeile M; Stavrou GA; Wacker F; Brüning R; Oldhafer KJ; Rodt T
    Abdom Radiol (NY); 2019 Oct; 44(10):3463-3479. PubMed ID: 31332502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diaphragmatic weakness after transcatheter arterial chemoembolization of the right inferior phrenic artery for treatment of hepatocellular carcinoma: a comparison of outcomes after N-butyl cyanoacrylate versus gelatin sponge embolization.
    Noh SY; Gwon DI; Park S; Yang WJ; Chu HH; Kim JW
    Acta Radiol; 2022 Jan; 63(1):48-58. PubMed ID: 33356351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the relationship between hepatocellular carcinoma location and transarterial chemoembolization efficacy.
    Miki I; Murata S; Uchiyama F; Yasui D; Ueda T; Sugihara F; Saito H; Yamaguchi H; Murakami R; Kawamoto C; Uchida E; Kumita SI
    World J Gastroenterol; 2017 Sep; 23(35):6437-6447. PubMed ID: 29085193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoembolization with cisplatin, lipiodol and Gelfoam and subsequent systemic chemotherapy with cisplatin and interferon in patients with hepatocellular carcinoma: a non-randomized prospective study.
    Baur M; Walter R; Gebauer A; Tscholakoff D; Lochs H; Mühlbacher F; Turetschek K; Binder R; Hudec M; Gangl A; Ferenci P; Dittrich C
    Int J Oncol; 2003 Sep; 23(3):811-9. PubMed ID: 12888922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative recurrence of hepatocellular carcinoma: results of transcatheter arterial chemoembolization.
    Park JH; Han JK; Chung JW; Han MC; Kim ST
    Cardiovasc Intervent Radiol; 1993; 16(1):21-4. PubMed ID: 8382109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.